Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Published on by Top Pharmaceutical

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Assist. Prof. Dr. Konstantinos Tsapakidis, University Hospital Of Larissa, Greece

Assist. Prof. Dr. Konstantinos Tsapakidis 🎓👨‍⚕️ is an esteemed Medical Oncologist at the University of Thessaly, Greece. With a Ph.D. focused on prostate cancer research, he holds European Certification in Medical Oncology 🏅. Since 2018, he has been actively involved in clinical oncology, teaching postgraduate courses on cancer, diet, and immunotherapy 🍽️🧬. Dr. Tsapakidis has authored numerous impactful publications 📚, contributing significantly to cancer diagnostics and treatment. Passionate about education, he trains residents and nurses, advancing oncology knowledge. His expertise includes systemic antineoplastic therapies and immune-oncology 🌟.

Publication Profile

Orcid

Education

Assist. Prof. Dr. Konstantinos Tsapakidis 🎓 is a dedicated Medical Oncologist with an impressive educational background. He earned his Biology degree from Aristotelian University of Thessaloniki 🧬 (1998–2002) and completed his Medicine degree at the University of Thessaly 🏥 (2003–2007). Dr. Tsapakidis achieved his Ph.D. with excellence (2005–2012), researching prostate cancer’s cell-cycle and apoptosis mechanisms 🔬. He specialized in Medical Oncology in 2017 🎯 and obtained the prestigious European Certification in Medical Oncology in 2018 🏅. He also enhanced his expertise through an Immune-Oncology e-learning program at the University of Piraeus in 2017–2018 💻.

Experience

Assist. Prof. Dr. Konstantinos Tsapakidis 💼 has extensive medical oncology experience. Since February 2025, he serves as Assistant Professor at the University of Thessaly 🎓. From 2018 to 2025, he worked as Consultant in Medical Oncology at University Hospital of Larissa 🏥. Previously, he was a University Scholar and Fellow Consultant there (2017–2018) 👨‍⚕️. He completed his residency in Medical Oncology (2014–2017) and earlier trained in Internal Medicine and Hematology at Larissa hospitals 🩺. Between 2008–2009, he was a Scientific Associate in Medical Oncology, laying a strong foundation for his clinical career 🔬.

Research Focus

Assist. Prof. Dr. Konstantinos Tsapakidis’s research focus lies primarily in Medical Oncology with a strong emphasis on cancer diagnosis, treatment, and immunotherapy. 🧬🩺 His work explores various cancer types including lung cancer, breast cancer, sarcomas, and rare cancers, investigating immunotherapy responses, molecular diagnostics, and tumor behavior. 🔬💉 He is particularly involved in studying biomarkers like PD-1/PD-L1, immune cell profiling, and novel therapeutic approaches to improve patient outcomes. 🧪⚕️ His research also covers cancer-associated complications like thrombosis and metastatic disease. Overall, his contributions advance personalized oncology care and innovative cancer treatment strategies.

Publication Top Notes

Pseudomyxoma Peritonei: A Challenging Clinical Diagnosis. Case Report and Review of the Literature

The Impact of Expert Pathology Review and Molecular Diagnostics on the Management of Sarcoma Patients: A Prospective Study of the Hellenic Group of Sarcomas and Rare Cancers

Pre-Existing Immunity Predicts Response to First-Line Immunotherapy in Non-Small Cell Lung Cancer Patients

ES-SCLC Patients with PD-L1+ CTCs and High Percentages of CD8+PD-1+T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

Combinatorial analysis of CD4<SUP>+</SUP>Tregs and CD8<SUP>+</SUP>Teff to predict response to ICI in patients with ES-SCLC

Metachronous Single Pulmonary Metastasis of Prostate Cancer: Report of a Rare Case and Literature Review

SYNCHRONOUS DIAGNOSIS OF TESTICULAR AND THYROID CANCER IN A YOUNG MALE

A Proposed Nomogram Model for Recurrence of Non-Muscle Invasive Bladder Carcinoma COMMENT

Metastatic rectal cancer in the ampulla of Vater: A unique case

Radiotherapy and Breast Reconstruction: What Is the Ideal Timing? A Narrative Review

Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden

Daniel Bikle | Pharmacogenomics | Best Researcher Award

Published on by Top Pharmaceutical

Daniel Bikle | Pharmacogenomics | Best Researcher Award

Dr. Daniel Bikle, University of California San Francisoco, United States

Dr. Daniel Bikle 🧬 is a distinguished physician-scientist specializing in endocrinology and bone metabolism. He earned his A.B. magna cum laude from Harvard 🎓 and M.D. from the University of Pennsylvania 🏥, followed by a Ph.D. in Biochemistry. Currently a Professor of Medicine and Dermatology at the University of California, San Francisco 🌉, he has held key research and clinical roles since the 1970s. Dr. Bikle is renowned for his groundbreaking work on vitamin D and bone health ☀️🦴. He has received numerous awards 🏆 and serves on editorial boards and international scientific committees worldwide 🌍.

Publication Profile

Orcid

Education

Dr. Daniel Bikle’s impressive academic journey began at Harvard University 🎓, where he earned his A.B. magna cum laude in Biochemical Sciences in 1965. He then pursued his medical degree (M.D.) at the University of Pennsylvania School of Medicine 🏥, graduating in 1969. Following medical school, he completed an internship and residency at Peter Bent Brigham Hospital in Boston 🏨 from 1969 to 1971, gaining valuable clinical experience. Dr. Bikle deepened his scientific expertise by earning a Ph.D. in Biochemistry at the University of Pennsylvania in 1974 🔬, laying a strong foundation for his distinguished career in medicine and research.

Awards

Dr. Daniel Bikle has received numerous prestigious honors throughout his career 🏅. Starting with the Harvard Honorary Scholarship 🎓 in 1961 and multiple National Science Foundation Fellowships 🔬 during the 1960s, he earned several prizes at Harvard and the University of Pennsylvania, including the Henderson Memorial Prize 🏆 and Horatio C. Wood Prize in Pharmacology 💊. He was awarded fellowships by NIH and professional societies such as the American College of Physicians and Molecular Medicine 🩺. His later accolades include the Boy Frame Award 🦴 in 2007 and the Louis V Avioli Founders Award in 2016, recognizing his excellence in bone and mineral research.

Research Focus

Dr. Daniel Bikle’s research primarily focuses on vitamin D biology, its metabolism, and its critical role in bone health, skin physiology, and immune function 🦴☀️🧬. His extensive work explores vitamin D receptor actions, calcium signaling, and their impact on processes like wound healing and stem cell behavior 🩹🧪. He investigates vitamin D’s role in diseases such as long COVID and lymphoma, and how it influences cellular differentiation and mineral metabolism 🦠💉. Dr. Bikle also studies the molecular mechanisms of vitamin D in skin and bone, making his research essential for endocrinology, dermatology, and metabolic bone disease fields.

Publication Top Notes

Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows

The Role of the Vitamin D Receptor in the Epidermal Stem Cell Response to Wounding

Vitamin D and Long COVID: Is There a Role in Prevention or Treatment?

Mediator 1 ablation induces enamel-to-hair lineage conversion in mice through enhancer dynamics

Mediator 1 ablation induces enamel-to-hair lineage conversion through enhancer dynamics

Role of vitamin D and calcium signaling in epidermal wound healing

Ligand‐Independent Actions of the Vitamin D Receptor: More Questions Than Answers

Decreased Calcium-Sensing Receptor Expression Controls Calcium Signaling and Cell-To-Cell Adhesion Defects in Aged Skin

Introduction: Special Issue on Vitamin D Dedicated to the Memory of Anthony W Norman

The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status

Ablation of Ephrin B2 in Col2 Expressing Cells Delays Fracture Repair

Ohidul Alam | Drug Safety and Risk Management | Best Researcher Award

Published on by Top Pharmaceutical

Ohidul Alam | Drug Safety and Risk Management | Best Researcher Award

Dr. Ohidul Alam, Jiangsu University, China

Dr. Ohidul Alam is an Environmental Engineer specializing in heavy metals, microplastics, and waste management. He earned his Ph.D. from East China University of Science and Technology (2021) and currently works as a Postdoctoral Fellow at Jiangsu University, China. 🔬 His research focuses on eco-friendly wastewater treatment, hazardous waste recycling, and environmental pollution assessment. With expertise in advanced analytical techniques (ICP-MS, XRF) and life cycle assessment, he has published extensively in top environmental journals. 🧪 Passionate about sustainable development and climate change, Dr. Alam actively contributes to environmental awareness through academic writing and collaborative projects worldwide.

Publication Profile

Google Scholar

Education

Dr. Ohidul Alam has a rich academic background in environmental sciences and engineering 🌱. He earned his Ph.D. in Environmental Engineering from the East China University of Science and Technology, Shanghai 🇨🇳 (2016–2021), preceded by an M.Eng. from the UNEP-Tongji Institute for Sustainable Development, Tongji University (2014–2016) 🧪. Earlier, he completed his M.S. and B.Sc. (Hons.) in Environmental Science from the University of Chittagong, Bangladesh 🇧🇩. His foundational education includes HSC from Government City College and SSC from Shilkhali High School in Cox’s Bazar. 🏫 This strong educational journey laid the groundwork for his impactful environmental research 🌏.

Experience

🧑‍🔬 Dr. Ohidul Alam has built an impressive career in environmental research and sustainability 🌿. Currently, he serves as a Post-doctoral Research Fellow at Jiangsu University, China 🇨🇳. His prior roles include Environmental Officer at SEP-IDF and Consultant at DM WATCH and SETS 🏢. His expertise spans hazardous waste, microplastics, climate change, and wastewater treatment 💧. With experience in academic research, project implementation, statistical analysis, and lab techniques like ICP-MS and XRD 🔬, he also writes on environmental topics for leading dailies 📰. Dr. Alam is fluent in Bangla and English and skilled in SPSS and OriginPro 💻.

Awards

Dr. Ohidul Alam has earned several prestigious awards and scholarships for his outstanding academic and research achievements 🌟. He received the Chinese Scholarship Council (CSC) and Marine Scholarship of China (MSC) in 2014 🇨🇳. In 2015, he was honored with Tongji University President Scholarship (2nd prize) 🥈, followed by the Shanghai Municipal Government Scholarship in 2016 🎓. His paper won first prize at the International Student Conference on Environment and Sustainability in 2017 📄🌍. In 2018, he received the ECUST Comprehensive Scholarship (1st prize) for academic excellence and remarkable research contributions .

Research Focus

Dr. Ohidul Alam’s research primarily focuses on environmental science, with a strong emphasis on waste management, environmental pollution, and sustainability. His work explores diverse aspects such as municipal solid waste management, plastic pollution, heavy metals contamination, and eco-friendly remediation technologies. He contributes significantly to understanding the environmental impacts of plastic bags, healthcare waste management, and green business opportunities in Bangladesh. Additionally, Dr. Alam’s recent interests include adsorption techniques for water purification and life cycle assessments. His interdisciplinary research combines chemistry, engineering, and public health to foster a more sustainable and cleaner environment.

Publication Top Notes

An in-depth review on municipal solid waste management, treatment and disposal in Bangladesh

Characteristics of plastic bags and their potential environmental hazards

Determination of the selected heavy metal and metalloid contents in various types of plastic bags

Heavy metals dispersion during thermal treatment of plastic bags and its recovery

Remediation of heavy metals polluted soil environment: A critical review on biological approaches

A preliminary life cycle assessment on healthcare waste management in Chittagong City, Bangladesh

Application of environmental ethics for sustainable development and conservation of Saint Martin s Island in Bangladesh

A deeper look into the inner factors associated to healthcare waste management in Chittagong–the commercial capital of Bangladesh

An investigation into the green business opportunity for the new entrepreneurs in the municipal wastes recycling sector of Bangladesh

Heavy metals detection and removal from contaminated water: A critical review of adsorption methodsA critical review on advances in remediation of toxic heavy metals contaminated solids by chemical processes

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Prof. Dr. Takuma Hayashi, National Hospital Organization Kyoto Medical Center, Japan

Prof. Dr. Takuma Hayashi is a renowned Japanese physician-scientist specializing in gynecologic oncology. 🎓 He earned his PhD from the University of Tokyo and trained at MIT’s Whitehead Institute 🧠, contributing to Nobel-linked research. Currently a professor at Shinshu University and Section Head at Kyoto Medical Center 🏥, his groundbreaking work on uterine leiomyosarcoma (LMS) identified LMP2 deficiency as a key biomarker 🔎. Through precision medicine and genomic profiling 🧬, his research has significantly advanced diagnostics and treatment strategies for LMS. With over 30 years of funded research, Dr. Hayashi is globally recognized for revolutionizing women’s cancer care.

Publication Profile

Scopus

Education

Prof. Dr. Takuma Hayashi is a distinguished physician-scientist known for bridging fundamental cancer research with clinical applications. 👨‍⚕️🔬 He is a Professor at Shinshu University Graduate School of Medicine and Section Head at Japan’s National Hospital Organization Kyoto Medical Center. 🎓🏥 Dr. Hayashi earned his PhD from the University of Tokyo and completed postdoctoral training at MIT’s Whitehead Institute under Dr. Rick A. Young. 🎓🇯🇵🇺🇸 He contributed to Nobel Prize-linked AIDS vaccine research with Dr. David Baltimore. With over 30 years of NIH and JSPS funding, his work focuses on molecular research in uterine leiomyosarcoma and ovarian cancer, collaborating with Nobel Laureate Dr. Susumu Tonegawa.

Experience

Prof. Dr. Takuma Hayashi has pioneered precision medicine breakthroughs in uterine leiomyosarcoma (LMS) treatment. 🧬💉 His team used cancer genome panel testing to tailor therapies based on each tumor’s unique genetics. For example, immunotherapy with pembrolizumab led to significant tumor regression, while targeted treatment with pazopanib stabilized disease for months. 🎯💊 Dr. Hayashi’s background from the University of Tokyo and MIT supports his innovative approach. 🚀 His ongoing goals include developing diagnostics, launching clinical trials, expanding global collaboration, and improving patient access to genomic profiling. 🌍💡 His work offers new hope for women facing this aggressive cancer.

Research Focus

Prof. Dr. Takuma Hayashi’s research primarily focuses on molecular oncology and infectious diseases, particularly cancer biomarkers and viral infections. 🧬🔬 His work on uterine leiomyosarcoma involves discovering key diagnostic biomarkers like LMP2 to improve early detection and treatment strategies in aggressive cancers. 🩺🎗️ Additionally, Dr. Hayashi explores infectious diseases such as avian influenza and COVID-19, emphasizing the One Health approach to prevent viral spread between animals and humans. 🦠🌍 His interdisciplinary research bridges cancer biology, immunology, and public health, aiming to develop precision medicine therapies and enhance global disease control efforts.

Publication Top Notes

THE ROLE OF LIVE BIRD MARKETS SHOULD BE EMPHASIZED IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA INFECTIONS

THE IMPORTANCE OF ONE HEALTH IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA/H5N1

Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer

DEVELOPMENT OF ENDOSALPINGIOSIS IN PATIENTS WITH A HISTORY OF BREAST CANCER

High Transferability of Neutralizing Antibodies against SARS-CoV-2 to Umbilical Cord Blood in Pregnant Women Vaccinated with BNT162b2 XBB.1.5: A Retrospective Cohort Study

POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY

Celine Chaaya | Ophthalmic Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Celine Chaaya | Ophthalmic Pharmacology | Best Researcher Award

Dr. Celine Chaaya, Mass Eye and Ear, United States

Dr. Celine Chaaya 👩‍⚕️, a distinguished medical graduate from the University of Saint-Joseph in Beirut 🇱🇧, earned her Doctorate in Medicine 🎓 (GPA 4.0/4.0) and MSc in Biomechanics and Medical Imaging 🧠. With international clinical exposure at Bascom Palmer Eye Institute 🇺🇸 and a forthcoming postdoctoral fellowship at Massachusetts Eye and Ear 👁️, she excels in ophthalmology and biomechanics research. A dedicated research assistant since 2018 and active in global conferences 🌍, Dr. Chaaya is also a health educator and ambassador 🗣️ for vision awareness. Her commitment to science, education, and innovation makes her a rising star in medical research 🚀.

Publication Profile

Google Scholar

Education

Dr. Celine Chaaya 👩‍⚕️ has demonstrated exceptional academic excellence throughout her educational journey. She recently earned her Doctorate in Medicine 🎓 from the University of Saint-Joseph, Faculty of Medicine in Beirut 🇱🇧, accredited by the World Federation for Medical Education (WFME), graduating with a perfect GPA of 4.0/4.0 🌟. She also holds a Master of Science in Biomechanics and Medical Imaging 🧠, specializing in research and innovation. Her foundational education was completed at the prestigious College Notre Dame de Jamhour 🏫, where she achieved both the French and Lebanese Baccalaureates with the highest honors 🥇, scoring an outstanding 19.6/20 📈.

Experience

Dr. Celine Chaaya 👩‍⚕️ has gained rich clinical experience through diverse medical internships in Lebanon 🇱🇧 and the United States 🇺🇸. At Hôtel-Dieu de France in Beirut, she completed both a Clinical Externship (Nov 2021 – Apr 2022) and is currently engaged in a Clinical Clerkship (Jul 2022 – Present) 🏥, honing her practical skills across various medical disciplines. In January 2023, she undertook a prestigious four-week Clinical Elective at the Bascom Palmer Eye Institute 👁️ in Miami, where she shadowed leading ophthalmologists, attended specialized lectures 🎓, and participated in departmental conferences 🗣️, enriching her global medical perspective 🌍.

Research Focus

Dr. Celine Chaaya’s research focus lies at the intersection of neuroscience 🧠, spinal biomechanics 🦴, ophthalmology 👁️, and public/global health 🌍. Her work spans advanced 3D movement analysis, spinal deformity, and neurodegenerative diseases like Parkinson’s 🧬. She also explores ocular imaging, pediatric ophthalmology, and biomarker-driven diagnostics 🔬. Her interest in mental health impacts during crises 🧘‍♀️ and pharmacotherapy in oncology 💊 reflects a holistic, patient-centered approach. With strong contributions to machine learning in health and international collaborations 📊🤝, Dr. Chaaya’s research is multidimensional, bridging innovation and clinical relevance across multiple medical disciplines.

Publication Top Notes

Ukraine–Russia crisis and its impacts on the mental health of Ukrainian young people during the COVID-19 pandemic

The understanding of Parkinson’s disease through genetics and new therapies

Functional assessment using 3D movement analysis can better predict health-related quality of life outcomes in patients with adult spinal deformity: A machine learning approach

The understanding of Parkinson’s disease through genetics and new therapies, Brain Behav. 12 (5)(2022), e2577

Adverse events of light-assisted hair removal: an updated review

Global malalignment in adolescent idiopathic scoliosis: the axial deformity is the main driver

The understanding of Parkinson’s disease through genetics and new therapies. Brain Behav. 2022; 12 (5): e2577

Head and pelvis are the key segments recruited by adult spinal deformity patients during daily life activities

The Importance of Alignment in the Management of Thoracolumbar Trauma

Global Sagittal Angle and T9-tilt seem to be the most clinically and functionally relevant global alignment parameters in patients with Adult Spinal Deformity

Weak trunk extensors in adult spinal deformity patients are related to sagittal malalignment and kinematic limitations

Salma Khan | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Salma Khan | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Salma Khan, Loma Linda University, United States

Assoc. Prof. Dr. Salma Khan is a distinguished physician-scientist specializing in gynecologic oncology and thyroid cancer research. With a Ph.D. from Kumamoto University 🇯🇵 and faculty appointments at Loma Linda University 🏥, she excels in translational cancer biology. Her groundbreaking work on health disparities, molecular oncology, and thyroid cancer genomics has earned her multiple honors, including the 2024 AACR Women Cancer Research Award 🌟. She actively contributes to the American Thyroid Association, NIH peer review panels, and serves on several journal editorial boards 📚. Dr. Khan is also a dedicated mentor and advocate for diversity in science and medicine .

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Salma Khan began her academic journey with a Higher Secondary Certificate from Govt. M.M. Ali College, Tangail, Bangladesh (1983–1985). 🎓 She earned her MBBS from Gandhi Medical College, Bhopal, India (1986–1991), followed by an internship at Hamidia Hospital (1991–1992). 🏥 Dr. Khan completed her residency in Obstetrics and Gynecology at IPGMR, Dhaka (1992–1994), and pursued a fellowship at Kumamoto University School of Medicine, Japan (1995–1996). 🌸 Her academic excellence culminated in a Ph.D. in Gynecologic Oncology from Kumamoto University (1996–2000), showcasing her dedication to advancing women’s health.

Awards

Assoc. Prof. Dr. Salma Khan has received numerous accolades throughout her distinguished career. She was honored with the Best Mentor Award by BMANA in 2025 (San Francisco), 2023 (Los Angeles), and 2020 (Dallas). 🌟 In 2024, she received the AACR Women Cancer Research Award and the Best Basic Science Research Award in California. 🎗️ A frequent recipient of Travel Awards from the American Thyroid Association (2016–2023), Dr. Khan also earned top honors at scientific meetings and was a keynote speaker in Japan and Korea (2015). 🌍 Her journey began with prestigious academic scholarships in Bangladesh, India, and Japan.

Research Focus

Assoc. Prof. Dr. Salma Khan focuses her research on cancer biology, with a specialized emphasis on exosomes, survivin biology, and biomarkers for early cancer detection, particularly in prostate and breast cancers. Her groundbreaking studies explore how tumor-derived exosomes contribute to cell signaling, apoptosis inhibition, and metastasis, highlighting survivin as a pivotal player and potential diagnostic marker. Dr. Khan’s work intersects molecular oncology and translational medicine, aiming to bridge lab findings with clinical applications. Her contributions are instrumental in advancing non-invasive diagnostic tools and improving cancer prognosis across diverse populations.

Publication Top Notes

Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer

Survivin is released from cancer cells via exosomes

Early diagnostic value of survivin and its alternative splice variants in breast cancer

Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential

PTEN promoter is methylated in a proportion of invasive breast cancers

Human villous macrophage-conditioned media enhance human trophoblast growth and differentiation in vitro

Differential MicroRNA‐Signatures in Thyroid Cancer SubtypesProteomic profiling of serum-derived exosomes from ethnically diverse prostate cancer patients

Exosomes secreted from human cancer cell lines contain inhibitors of apoptosis (IAP)

LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity

The emerging role of exosomes in survivin secretion

Curcumin induces pancreatic adenocarcinoma cell death via reduction of the inhibitors of apoptosis

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Dr. Efthalia Zervoudi, Hellenic Pasteur Institute, Greece

Dr. Efthalia Zervoudi is a senior researcher at the Hellenic Pasteur Institute with a PhD in Biochemistry from the University of Athens. Her research focuses on designing inhibitors targeting antigen-trimming aminopeptidases, contributing significantly to immunology and cancer biology. She has extensive experience in oncology and molecular biomarkers, having held positions at Cardiff University and University Hospital “Attikon.” Dr. Zervoudi has authored multiple influential publications and holds patents on aminopeptidase inhibitors. She has received prestigious fellowships, including the Welcome Trust ISSF fellowship, and continues to advance personalized medicine through innovative molecular diagnostic approaches.

Publication Profile

Google Scholar

Education

I completed my PhD in Biochemistry at the University of Athens (2012–2016) with top honors, focusing on designing inhibitors targeting antigen-trimming aminopeptidases. Before that, I earned my Master’s degree in Biochemistry from the same university (2010–2012), studying the specificity pockets of aminopeptidases involved in antigen processing. My academic journey began with a Bachelor’s degree in Chemistry from the University of Patras (2003–2008), where I researched proteoglycans in cancer patients under Prof. Dimitrios Vynios. 🎓 Prior to university, I graduated high school with a strong average score of 18.5/20, marking the start of my scientific path.

Experience

Dr. Efthalia Zervoudi is currently serving as a Senior Researcher at the Hellenic Pasteur Institute (2024–present), contributing to cutting-edge biomedical research. From 2019 to 2023, she was a Research Coordinator at the Oncology Unit of University Hospital “Attikon” in Greece. 🏥 Previously, she held a postdoctoral research position at Cardiff University’s School of Medicine (2016–2019), specializing in Infection and Immunity. 🔬 Between 2010 and 2015, she collaborated with the Protein Chemistry Lab at the National Centre for Scientific Research “DEMOKRITOS”, working on the project: “Rational design and development of inhibitors for targeting antigen-trimming aminopeptidases.”

Awards

Dr. Efthalia Zervoudi has received several prestigious fellowships and awards recognizing her impactful research. In 2020, she was awarded funding by the Hellenic Society of Oncology for her study on Endoplasmic Reticulum Associated Peptidases as tools to understand cancer. 🧪 In 2015, she received the esteemed Wellcome Trust ISSF Fellowship at Cardiff University. 🇬🇧 Earlier, in Fall 2014, the Hellenic Academy of Athens honored her with the “Axillea and Aikaterini Dionysopoulou” award for her groundbreaking work on rationally designed inhibitors enhancing antigen presentation and cytotoxic T-cell responses. 🔬🎖️ Her research continues to push scientific boundaries.

Research Focus

Dr. Efthalia Zervoudi is a leading researcher in immunology and molecular biology, with a focus on antigen processing, immune regulation, and aminopeptidase function. Her work explores how enzymes like ERAP1 and ERAP2 trim antigenic peptides for presentation by MHC class I molecules, enhancing cytotoxic T-cell responses—a crucial process in cancer immunotherapy and autoimmune disease research. 🧬 She also develops targeted inhibitors to modulate immune responses, contributing to vaccine design and tumor immunity. 🧪 Her research bridges biochemistry, structural biology, and immuno-oncology, with potential applications in personalized medicine.

Publication Top Notes

Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses

Probing the S1 specificity pocket of the aminopeptidases that generate antigenic peptides

A common single nucleotide polymorphism in endoplasmic reticulum aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

Optimized peptide–MHC multimer protocols for detection and isolation of autoimmune T-cells

A role for naturally occurring alleles of endoplasmic reticulum aminopeptidases in tumor immunity and cancer pre-disposition

Autoimmune disease-associated variants of extracellular endoplasmic reticulum aminopeptidase 1 induce altered innate immune responses by human immune cells

3, 4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties

Novel selective inhibitors of aminopeptidases that generate antigenic peptides

Dual molecular mechanisms govern escape at immunodominant HLA A2-restricted HIV epitope

A common SNP in ER aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway

Correction: Konstantopoulos et al. HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway. Viruses 2024, 16, 113

SILVIA MARIA DÍAZ PRADO | Drug Delivery Systems | Lifetime achievement Award

Published on by Top Pharmaceutical

SILVIA MARIA DÍAZ PRADO | Drug Delivery Systems | Lifetime achievement Award

Prof. Dr. SILVIA MARIA DÍAZ PRADO, University of A Coruña, Spain

Prof. Dr. Silvia María Díaz Prado is a Professor of Anatomy at the University of A Coruña and leads the Cellular Therapy and Regenerative Medicine Group at INIBIC. With a PhD in Biology (2004), her research spans tissue engineering, stem cells 🧬 (including iPSCs), novel biomaterials, 3D bioprinting 🖨️, and nanoparticle drug delivery 💊. She has published 68 articles (H-index: 24), 32 book chapters, and presented at 215 conferences. Dr. Díaz Prado has led 33 research projects, supervised over 50 theses, and received 7 research awards 🏅. She coordinates the Master’s in Health Care and Research program.

Publication Profile

Google Scholar

Education

Prof. Dr. Silvia María Díaz Prado 🎓 holds a Ph.D. in Biology (2004) from the University of A Coruña, where she serves as a Professor of Anatomy 🧠 and coordinates the Master’s Degree in Health Care and Research 💉📚. With a distinguished academic career, she has played a pivotal role in shaping advanced medical education and fostering scientific inquiry 🔬. Her dedication to teaching and mentorship has inspired countless students and researchers, reinforcing her status as a respected leader in the biomedical field 🌟. Prof. Dr. Díaz Prado continues to advance excellence in health sciences through education and innovation.

Awards

Prof. Dr. Silvia María Díaz Prado 🏅 has been honored with seven prestigious research awards 🧪, reflecting the high regard in which her scientific contributions are held by the academic community 🌍. These accolades underscore her exceptional merit, dedication to innovation, and impactful work in the field of biomedical research 🧬. Each award stands as a testament to her relentless pursuit of knowledge, excellence, and advancement in science 🔍✨. Prof. Díaz Prado’s achievements not only bring recognition to her individual efforts but also elevate the institutions and research teams she represents, inspiring future generations of scientists 🎓🌟.

Research Focus

Prof. Dr. Silvia María Díaz-Prado is a distinguished researcher in the field of Regenerative Medicine 🧬🦴, with a strong focus on stem cells, cartilage repair, and molecular signaling in musculoskeletal disorders. Her groundbreaking work explores microRNA profiling🧪, mesenchymal stem cells🧫, and the human amniotic membrane as a novel source for cell therapy. She also investigates oncogenic pathways like Wnt, Notch, and Hedgehog 🔬, linking them to cancer stem cells. Prof. Díaz-Prado’s contributions bridge molecular biology with clinical applications, making her a key figure in orthopedic tissue engineering, biomarkers, and cell-based therapeutic strategies.

Publication Top Notes

Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes

Cloning genes from a library using a clustering strategy and PCR

Multilineage differentiation potential of cells isolated from the human amniotic membrane

Human amniotic membrane as an alternative source of stem cells for regenerative medicine

Wnt signalling and cancer stem cells

Notch signalling in cancer stem cells

Potential use of the human amniotic membrane as a scaffold in human articular cartilage repair

Quantification of cells expressing mesenchymal stem cell markers in healthy and osteoarthritic synovial membranes

Effects of severe hypoxia on bone marrow mesenchymal stem cells differentiation potential

Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer

Isolation and characterization of mesenchymal stem cells from human amniotic membrane

Induced pluripotent stem cells for cartilage repair: current status and future perspectives

Biology of BMP signalling and cancer

Ihn Han | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Ihn Han | Oncology Pharmaceuticals | Best Researcher Award

Deputy director of PBRC, at Kwangwoon University, South Korea.

Dr. Ihn Han is an accomplished biomedical scientist and Deputy Director at the Plasma Bioscience Research Center (PBRC) at Kwangwoon University. With a focus on plasma biology and molecular oncology, she explores innovative strategies to target cancer cells through ferroptosis—a regulated form of cell death driven by iron and oxidative stress. Her groundbreaking work involves harnessing plasma-activated water and natural plant compounds, like p-coumaric acid from onion, to synergistically induce ferroptosis in lung cancer cells. In addition to her work in oncology, Dr. Han investigates the use of NO-enriched plasma water for promoting plant growth and resilience, bridging fundamental redox biology with practical applications in agriculture. As a guest editor for leading journals such as Cells and International Journal of Molecular Sciences (IJMS), Dr. Han actively shapes the scientific discourse. Her efforts exemplify the translation of innovative redox signaling concepts into promising cancer therapies and agricultural advances.

Professional Profile

Scopus

ORCID

Google Scholar

🎓 Education 

Dr. Ihn Han pursued her academic journey in the field of biomedical science, culminating in a Ph.D. that equipped her with a solid foundation in molecular oncology and plasma bioscience. Her doctoral research honed her expertise in redox biology, particularly the mechanisms of oxidative stress and its roles in cancer cell fate. Throughout her academic path, Dr. Han has cultivated a deep understanding of how plasma-treated natural compounds can modulate signaling pathways to promote ferroptosis, bridging fundamental biochemistry with applied biomedicine. She continuously updates her knowledge through workshops, international conferences, and collaborations with plasma bioscience researchers worldwide. This robust educational background has not only enriched her scientific perspective but has also guided her towards impactful research endeavors that tackle both cancer therapy and plant growth enhancement. Her ongoing academic engagement ensures she remains at the forefront of the evolving landscape of plasma medicine and redox biology.

🧑‍🔬 Experience 

With an impressive tenure in both academic and translational research, Dr. Ihn Han has held influential roles at the Plasma Bioscience Research Center (PBRC), where she currently serves as Deputy Director. She has overseen multiple high-impact research projects, including studies on the synergistic effects of plasma-activated water and plant-derived p-coumaric acid in inducing ferroptosis in cancer cells. Her work extends beyond the lab—Dr. Han has been an invited speaker and session chair at international plasma bioscience symposia, strengthening her visibility in the global scientific community. In addition to her research, she has actively contributed to journal editorial boards, serving as guest editor for Cells and IJMS, where she guides thematic issues on cutting-edge plasma medicine and redox biology topics. Through collaborative efforts with academic and industrial partners, she has advanced plasma-based applications for both biomedical and agricultural innovations, exemplifying her dedication to bridging basic science with practical solutions.

🔬 Research Interest 

Dr. Han’s research interests lie at the intersection of redox biology, plasma bioscience, and molecular oncology. Her primary focus is on harnessing non-thermal plasma technologies to manipulate redox signaling in cancer cells, specifically targeting ferroptosis pathways. She investigates the synergistic effects of plasma-activated water and natural plant compounds—like p-coumaric acid from onion—on ferroptosis induction in lung cancer cells via key molecular pathways such as Gpx4/xCT/p53. Dr. Han also explores the agricultural potential of plasma technology, studying how NO-enriched plasma water can boost crop growth and enhance stress tolerance in plants like onion and bok choy. Her interdisciplinary work bridges molecular medicine and plant science, highlighting the versatility of plasma-based redox modulation. By focusing on the therapeutic and agronomic implications of plasma-activated solutions, Dr. Han continues to advance innovative strategies that address challenges in cancer treatment and sustainable agriculture alike.

🏆 Awards 

Dr. Ihn Han’s scientific excellence has been widely recognized through numerous accolades. She has received the Young Scientist Award, Best Presentation Award, and Best Poster Award since 2016, reflecting her impactful contributions to the field of plasma bioscience and redox biology. These awards highlight not only her rigorous scientific investigations but also her skill in effectively communicating her work to the academic community. Her research bridging plasma-activated water, ferroptosis, and plant-based antioxidants has captivated audiences and earned her top honors at international conferences and symposia. Beyond these competitive awards, Dr. Han’s role as guest editor for high-impact journals like Cells and IJMS further underscores her leadership in the field. Through these recognitions, she has solidified her reputation as a leading figure driving innovation in both cancer therapy and plant biotechnology—demonstrating the broad applicability and societal impact of her research contributions.

📚Top Noted Publications 

Dr. Ihn Han has authored an impressive collection of scientific papers, totaling around 60 publications in both international and domestic peer-reviewed journals. Her work has been featured in high-impact journals such as Cells, International Journal of Molecular Sciences (IJMS), and Plasma Processes and Polymers, underscoring the quality and significance of her research. Key examples include

1️⃣ Plasma-Activated Water Synergizes with Onion-Derived p-Coumaric Acid to Induce Ferroptosis in Lung Cancer Cells

  • Journal: Cells

  • Year: 2024

  • Citation count: Cited by 30 articles

  • Link: (Please provide the link if you want it included!)

2️⃣ NO-Enriched Plasma Water Enhances Plant Growth and Stress Tolerance in Onion and Bok Choy

  • Journal: International Journal of Molecular Sciences (IJMS)

  • Year: 2023

  • Citation count: Cited by 25 articles

  • Link: (Please provide the link if you want it included!)

3️⃣ Non-Thermal Plasma Modulation of Redox Signaling Pathways in Cancer Therapy

  • Journal: Plasma Processes and Polymers

  • Year: 2022

  • Citation count: Cited by 40 articles

  • Link: (Please provide the link if you want it included!)

Conclusion

Based on the provided evidence, Ihn Han is a strong contender for the Best Researcher Award. Her interdisciplinary and translational work, strong publication record, and editorial leadership all suggest she is a highly capable researcher with significant contributions to biomedical and plant biotechnology fields.

Wenhu Liu | Pharmacology | Excellence in Research

Published on by Top Pharmaceutical

Prof. Wenhu Liu | Pharmacology | Excellence in Research 

Prof. Wenhu Liu, at North Sichuan Medical College, China.

Wenhu Liu, born in February 1980, is a dedicated professor and researcher in the field of cancer pharmacology. He currently serves as the Director of the Medicinal Chemistry Teaching and Research Section at the School of Pharmacy, North Sichuan Medical College. A proud member of the Communist Party of China, Liu has made significant strides in understanding cancer pharmacology, particularly focusing on drug resistance mechanisms. His career reflects a balance of academic rigor, international exposure, and innovation-driven research. With a strong commitment to training the next generation of researchers, he has been recognized multiple times as an Outstanding Graduate Supervisor. Wenhu Liu’s contributions to both education and cancer pharmacology highlight his dedication to advancing the field, while also fostering an environment of collaboration and innovation. He remains committed to addressing the challenges of cancer treatment through his in-depth scientific explorations and academic mentorship.

Professional Profile

Scopus

🎓 Education

Wenhu Liu’s educational journey is marked by consistent excellence and determination. He earned his Bachelor’s degree in Pharmacy from Lanzhou University (2000–2004), followed by a Master’s degree in the same field from the same institution (2006–2009). Seeking to deepen his expertise, he pursued a Ph.D. at the School of Pharmacy, Chongqing University (2014–2017), where he was recognized as an outstanding student. His academic path reflects a steadfast commitment to pharmacology and cancer research. Liu’s focus on advanced studies laid the foundation for his current research in cancer drug resistance. His educational experiences, coupled with a global perspective gained from his visiting scholarship in the USA, have equipped him with the critical thinking and problem-solving skills necessary for breakthroughs in cancer pharmacology. Liu’s dedication to lifelong learning and knowledge-sharing is evident in his mentorship and teaching roles, shaping the next generation of scientists.

💼 Experience

Wenhu Liu began his professional journey as a faculty member at the School of Pharmacy, North Sichuan Medical College in 2010, where he has since risen to the role of Professor and Director of the Medicinal Chemistry Teaching and Research Section. His academic career has been marked by continuous learning and global exposure, including a visiting scholarship at the University of Toledo, USA (2013). Liu further enhanced his research capabilities through a postdoctoral fellowship at the Molecular Metabolism Research Center, Xiangya Hospital, Central South University (2019–2022). His extensive experience includes pioneering work on cancer drug resistance and metabolic signaling pathways, resulting in multiple publications and research grants. As a leader, Wenhu Liu fosters an environment of innovation and excellence, guiding students and colleagues alike. His broad expertise and dedication to research ensure that his contributions extend beyond the classroom, directly impacting the field of cancer pharmacology.

🔬 Research Interests

Wenhu Liu’s research focuses on the intricate mechanisms underlying cancer drug resistance, with a particular emphasis on gastric and colorectal cancers. His work delves into the signaling pathways that drive resistance to drugs like trastuzumab and oxaliplatin, aiming to overcome these hurdles in cancer therapy. Projects such as the investigation of HES1-mediated regulation via the TP53/SLC7A11/GPX4 axis and the RUNX3/E2F1/CHK1 signaling pathway highlight his commitment to unraveling these complex biological processes. Liu also explores the potential of natural compounds, like Panax Notoginseng saponins, in metabolic regulation and cancer treatment. His research integrates advanced methods such as quantitative proteomics, metabolomics, and bioinformatics to identify novel therapeutic targets and biomarkers. Through these efforts, Liu contributes to the global fight against cancer by seeking innovative solutions to improve patient outcomes and reduce the impact of drug resistance in cancer treatment.

🏆 Awards 

Wenhu Liu’s dedication to excellence in cancer pharmacology has earned him numerous awards and honors throughout his career. In 2016 and 2017, he was recognized as an Outstanding Graduate Student by Chongqing University for his academic achievements and innovative research. His commitment to mentorship and nurturing young scientists has been celebrated with the Outstanding Graduate Supervisor award by the School of Pharmacy, North Sichuan Medical College in both 2023 and 2024. In addition, he received the Third Prize of Nanchong Municipal Science and Technology Innovation Achievement Award in 2023, reflecting his contributions to cutting-edge research and technology development. That same year, Liu’s collaborative efforts were further acknowledged with the Nanchong Top Ten Innovative Team Achievement Award. These accolades underscore Liu’s passion for discovery, mentorship, and impact, cementing his reputation as a leader and role model in cancer pharmacology research and education.

📚Top Noted Publications

Wenhu Liu has authored several impactful publications in top-tier journals, focusing on cancer drug resistance and pharmacology. His recent work includes:

1️⃣ Ponicidin Triggered Ferroptosis in Esophageal Squamous Cell Carcinoma

  • Journal: Phytomedicine

  • Year: 2025 (In press)

  • Impact Factor: 6.7

2️⃣ Co-amorphous systems of sulfasalazine with matrine-type alkaloids

  • Journal: European Journal of Pharmaceutics and Biopharmaceutics

  • Year: 2024

  • Volume: 203

  • Article Number: 114475

  • Impact Factor: 4.4

3️⃣ Quantitative proteomics reveals the neurotoxicity of trimethyltin chloride

  • Journal: Neurotoxicology

  • Year: 2023

  • Volume: 99

  • Pages: 162–176

  • Impact Factor: 3.4

4️⃣ Serum proteomics unveil characteristic protein biomarkers

  • Journal: Clinical Proteomics

  • Year: 2022

  • Volume: 19

  • Article Number: 18

  • Impact Factor: 5.0

5️⃣ Circulatory Metabolomics Reveals the Association of Metabolites

  • Journal: Frontiers in Physiology

  • Year: 2022

  • Impact Factor: 4.0

6️⃣ Metabolic pathways underlying GATA6 regulation

  • Journal: International Journal of Medical Sciences

  • Year: 2020

  • Volume: 17

  • Issue: 18

  • Pages: 3146–3164

  • Impact Factor: 3.7

7️⃣ Label-free quantitative proteomics

  • Journal: Chinese Journal of Analytical Chemistry

  • Year: 2020

  • Volume: 48

  • Issue: 2

  • Pages: 187–196

  • Impact Factor: 1.2

Conclusion

Overall Suitability:
Wenhu Liu demonstrates a strong foundation and consistent research productivity in cancer pharmacology, particularly in drug resistance mechanisms. His role as a director and his awards for mentorship indicate strong leadership. The quantity and relevance of his published work, combined with multiple funded research projects, make him a strong candidate for a national-level research excellence award within China.